Subtopic Deep Dive
TNF-alpha Inhibitors in Hidradenitis Suppurativa
Research Guide
What is TNF-alpha Inhibitors in Hidradenitis Suppurativa?
TNF-alpha inhibitors are biologic drugs like adalimumab and infliximab that block tumor necrosis factor-alpha to treat moderate-to-severe hidradenitis suppurativa (HS) by reducing inflammation and lesion severity.
Clinical trials demonstrate adalimumab's efficacy in HS, with phase 3 studies showing higher response rates versus placebo at 12 weeks (Kimball et al., 2016, 734 citations). Guidelines recommend TNF inhibitors for Hurley stage II-III HS (Zouboulis et al., 2015, 1046 citations). Real-world studies use IHS4 scoring for dynamic severity assessment (Zouboulis et al., 2017, 427 citations).
Why It Matters
TNF-alpha inhibitors like adalimumab improve Hurley stage outcomes and achieve remission in moderate-to-severe HS patients unresponsive to conventional therapies (Kimball et al., 2016). European guidelines position them as first-line biologics, enhancing quality of life by reducing painful nodules and abscesses (Zouboulis et al., 2015). Kimball et al. (2012, 405 citations) established adalimumab's role in systemic HS management, influencing FDA approval and transforming dermatology practice.
Key Research Challenges
Variable Response Predictors
Predictors of TNF inhibitor response in HS remain unclear, with heterogeneous patient outcomes across Hurley stages. Kimball et al. (2016) reported 46-52% response rates at 12 weeks, but long-term predictors are undefined. Zouboulis et al. (2017) highlight IHS4 limitations in capturing individual variability.
Long-term Safety Profiles
Safety data beyond 12 weeks for adalimumab and infliximab in HS is limited, with risks of infections and comorbidities. Kimball et al. (2012) noted similar serious adverse events to placebo short-term, but extended monitoring is needed. Guidelines stress ongoing pharmacovigilance (Zouboulis et al., 2015).
Optimal Dosing Strategies
Standard weekly adalimumab dosing may not suit all HS severities, lacking personalization. Phase 3 trials used 40 mg weekly (Kimball et al., 2016), but dose escalation needs remain unaddressed. IHS4 enables dynamic adjustment, yet protocols are inconsistent (Zouboulis et al., 2017).
Essential Papers
European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa
Christos C. Zouboulis, Nemesha Desai, Lennart Emtestam et al. · 2015 · Journal of the European Academy of Dermatology and Venereology · 1.0K citations
Abstract Hidradenitis suppurativa/acne inversa ( HS ) is a chronic, inflammatory, recurrent, debilitating skin disease of the hair follicle that usually presents after puberty with painful, deep‐se...
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
Alexa B. Kimball, Martin M. Okun, David Williams et al. · 2016 · New England Journal of Medicine · 734 citations
Treatment with adalimumab (40 mg weekly), as compared with placebo, resulted in significantly higher clinical response rates in both trials at 12 weeks; rates of serious adverse events were similar...
Development and validation of the International Hidradenitis Suppurativa Severity Score System ( <scp>IHS</scp> 4), a novel dynamic scoring system to assess <scp>HS</scp> severity
Christos C. Zouboulis, Thrasyvoulos Tzellos, Αthanassios Kyrgidis et al. · 2017 · British Journal of Dermatology · 427 citations
The novel IHS4 is a validated tool to dynamically assess HS severity and can be used both in real-life and the clinical trials setting.
Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Alexa B. Kimball, Francisco A. Kerdel, David R. Adams et al. · 2012 · Annals of Internal Medicine · 405 citations
Abbott Laboratories.
Etiology and Management of Pyoderma Gangrenosum
Iris Ahronowitz, Joanna Harp, Kanade Shinkai · 2012 · American Journal of Clinical Dermatology · 395 citations
Curcumin: an orally bioavailable blocker of <scp>TNF</scp> and other pro‐inflammatory biomarkers
Bharat B. Aggarwal, Subash C. Gupta, Bokyung Sung · 2013 · British Journal of Pharmacology · 387 citations
TNFs are major mediators of inflammation and inflammation‐related diseases, hence, the U nited S tates F ood and D rug A dministration ( FDA ) has approved the use of blockers of the cytokine, TNF ...
Hidradenitis suppurativa
J. Revuz · 2009 · Journal of the European Academy of Dermatology and Venereology · 329 citations
Hidradenitis suppurativa is a chronic disease characterized by recurrent, painful, deep-seated, rounded nodules and abscesses of apocrine gland-bearing skin. Subsequent suppuration, sinus tracts an...
Reading Guide
Foundational Papers
Start with Kimball et al. (2012, 405 citations) for adalimumab's initial efficacy proof in moderate-severe HS, then Zouboulis et al. (2015, 1046 citations) for treatment guidelines integrating TNF inhibitors.
Recent Advances
Study Kimball et al. (2016, 734 citations) phase 3 trials confirming adalimumab approval; Zouboulis et al. (2017, 427 citations) for IHS4 validation in monitoring responses.
Core Methods
Core techniques: HiSCR endpoint (lesion/abscess reduction); IHS4 scoring (points for nodules, tunnels, draining); weekly subcutaneous adalimumab 40 mg dosing from RCTs.
How PapersFlow Helps You Research TNF-alpha Inhibitors in Hidradenitis Suppurativa
Discover & Search
PapersFlow's Research Agent uses searchPapers and citationGraph to map TNF inhibitor literature from Kimball et al. (2016) central node, revealing 734 citing papers on adalimumab trials. exaSearch uncovers real-world HS studies beyond OpenAlex indexes, while findSimilarPapers links Zouboulis et al. (2015) guidelines to efficacy data.
Analyze & Verify
Analysis Agent applies readPaperContent to extract IHS4 response rates from Zouboulis et al. (2017), then verifyResponse (CoVe) cross-checks claims against Kimball et al. (2016) trial data. runPythonAnalysis computes meta-analysis statistics on remission rates using pandas/NumPy; GRADE grading assesses evidence quality for adalimumab (high) versus infliximab (moderate).
Synthesize & Write
Synthesis Agent detects gaps like long-term infliximab data via contradiction flagging across trials. Writing Agent uses latexEditText for HS guideline revisions, latexSyncCitations to integrate Zouboulis et al. (2015), and latexCompile for publication-ready reviews; exportMermaid visualizes trial flowcharts.
Use Cases
"Run meta-analysis on adalimumab response rates in HS phase 3 trials by Hurley stage."
Research Agent → searchPapers('adalimumab HS phase 3') → Analysis Agent → runPythonAnalysis(pandas meta-analysis on Kimball 2016 data) → CSV export of pooled HiSCR rates (50% Hurley II, 30% Hurley III).
"Draft LaTeX review section on TNF inhibitors citing Zouboulis guidelines."
Synthesis Agent → gap detection → Writing Agent → latexEditText('TNF HS review') → latexSyncCitations(Zouboulis 2015, Kimball 2016) → latexCompile → PDF with formatted trial tables.
"Find code for IHS4 severity calculator from HS papers."
Research Agent → paperExtractUrls(Zouboulis 2017) → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python script for dynamic IHS4 computation from lesion counts.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ TNF inhibitor papers, chaining searchPapers → citationGraph → GRADE grading for structured efficacy report. DeepScan's 7-step analysis verifies adalimumab safety claims from Kimball et al. (2016) with CoVe checkpoints. Theorizer generates hypotheses on IL-17/TNF synergies from Kelly et al. (2015) cytokine data.
Frequently Asked Questions
What defines TNF-alpha inhibitors in HS treatment?
TNF-alpha inhibitors like adalimumab block TNF to reduce HS inflammation; adalimumab is FDA-approved based on phase 3 trials showing 46% HiSCR response (Kimball et al., 2016).
What are key methods for evaluating TNF inhibitors in HS?
HiSCR (Hiadradenitis Suppurativa Clinical Response) measures ≥50% lesion reduction; IHS4 dynamically scores severity (Zouboulis et al., 2017). Phase 3 trials used weekly 40 mg adalimumab (Kimball et al., 2016).
What are the most cited papers on this topic?
Top papers: Zouboulis et al. (2015, 1046 citations, guidelines); Kimball et al. (2016, 734 citations, phase 3 trials); Kimball et al. (2012, 405 citations, early adalimumab study).
What open problems exist in TNF-alpha inhibitors for HS?
Challenges include response predictors, long-term safety beyond 52 weeks, and optimal dosing for Hurley III; infliximab real-world data lags adalimumab (Zouboulis et al., 2015).
Research Hidradenitis Suppurativa and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching TNF-alpha Inhibitors in Hidradenitis Suppurativa with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers